Comparative QSAR Analysis of Estrogen Receptor Ligands

Total Page:16

File Type:pdf, Size:1020Kb

Comparative QSAR Analysis of Estrogen Receptor Ligands Chem. Rev. 1999, 99, 723−744 723 Comparative QSAR Analysis of Estrogen Receptor Ligands Hua Gao,† John A. Katzenellenbogen,‡ Rajni Garg,† and Corwin Hansch*,† Departments of Chemistry, Pomona College, Claremont, California 91711, and University of Illinois, 600 South Mathews Avenue, Urbana, Illinois 61801 Received April 27, 1998 (Revised Manuscript Received November 18, 1998) Contents I. Introduction I. Introduction 723 In recent years, the need for agents for the treat- II. Methods 725 ment of hormone-responsive cancers and the mecha- III. Results 726 nistic toxicological studies of environmental pollut- 1. Estradiol Derivatives 726 ants have sparked a great deal of scientific interest and research into the chemical and biological inter- A. Relative Binding Affinities (RBA) of 726 16R-Substituted Estradiols with Rat actions between estrogen receptors and their ligands. Uterine Estrogen Receptor at 0 °C Breast cancer is the most frequently diagnosed 1 B. Relative Binding Affinities of 727 cancer in women and a major cause of cancer. Since 11â-Substituted Estradiols with Mouse estrogens are known to play a role in the develop- Uterine Estrogen Receptor ment and growth of many breast cancers, a logical C. Relative Binding Affinities of 727 approach for the treatment of estrogen-sensitive 17R-Substituted Estradiols with Rat breast cancer is the use of antiestrogens that block Uterine Estrogen Receptor at 0 °C the interaction of estrogens with their specific D. Relative Binding Affinities of 17R-XCHd 728 receptor. Several classes of antiestrogens have been CH-estradiols with Rat Uterine Estrogen developed for the treatment of breast cancer, but Receptor unfortunately, although the initial response of breast E. Relative Binding Affinities of 11â-, 16R-, 729 cancer to hormone therapy can be substantial, resis- and 17R-Substituted Estradiols with Lamb tance to estrogen antagonist therapy often devel- Uterine Estrogen Receptor ops.2,3 Tamoxifen (Nolvadex), the antiestrogen most F. Relative Binding Affinities of 730 frequently used in breast cancer hormone therapy 7R-Undecylestradiol Derivatives with Calf has mixed agonist-antagonist properties; other more Uterine Estrogen Receptor recently developed antiestrogens, such as ICI G. Relative Binding Affinities of 730 182,780, are pure antiestrogens and may prove to be Multisubstituted Estradiols with Receptors more effective in breast cancer treatment.4 Anties- of Mouse Mammary Epithelial Cells trogens are also being studied as agents to prevent 2. Nonsteroidal Compounds 731 breast cancer in women at high risk.5 A. Metahexestrol and Hexestrol Derivatives 731 Estrogens are also widely prescribed in meno- B. Indenes and Indenones 732 pausal women as hormone replacement therapy to C. 2-Phenylindole Derivatives 733 maintain bone mineral density and preserve cardio- D. Benzothiophenes 734 vascular health. The use of agents, such as Raloxifene E. Triphenylacrylonitrile Derivatives 737 (Evista), that have a favorable balance of agonist F. Increase in the Proliferation of MCF-7 737 activities in certain tissues (bone, liver, vasculature) Cells (EC ) with Triphenylacrylonitriles and antagonist activities in other tissues (uterus and 50 6,7 G. 1,1-Diphenylethylenes 738 breast) is favored for such uses because of their reduced risk in promoting tumor development and H. Antiestrogenicity of 1,1-Diphenylethylenes 739 growth in these tissues, and there are many active I. Estrogenic Activity of 739 programs of research in academic and industrial 4,4′-Dihydroxydiphenylmethanes in Rats laboratories aimed at the development of such tissue- J. MCF-7 Cell Proliferation by Simple 740 selective estrogens. Phenols in Cells Free of Natural Estrogens The finding that compounds from the environment, of both synthetic and natural origin, can interfere K. MCF-7 Cell Proliferation by 4-HOC6H4C- 741 (X)(Y)C H -4′-OH with sexual development and reproductive function 6 4 has led to intense investigations of these endocrine- IV. Discussion 741 disruptive substances.8 Many (though not all9,10) V. Acknowledgment 743 endocrine disrupters are estrogens and exert agonist VI. References 743 and antagonist effects through the estrogen recep- tor: those that are synthetic include pesticides, food antioxidants, and metabolites of nonionic surfac- * To whom correspondence may be addressed. 11 † Pomona College. tants; naturally occurring ones are plant secondary ‡ University of Illinois. metabolites and mold metabolites.8 Among the latter 10.1021/cr980018g CCC: $35.00 © 1999 American Chemical Society Published on Web 02/19/1999 724 Chemical Reviews, 1999, Vol. 99, No. 3 Gao et al. Hua Gao received his Ph.D. in Pharmaceutical Sciences at the University Rajni Garg received her M.Sc. in Chemistry (1984) from Meerut University of Southern California. He joined Professor Corwin Hansch in 1995 as a and M.Phil. (1988) degree from Delhi University, India. Her M.Phil. postdoctoral research associate and worked with BioByte Corporation as dissertation work was on peptide synthesis. She was a faculty member a scientist. Currently, he is working with MDS Panlabs as a scientist in in the Chemistry Department of Birla Institute of Technology and Science, Computational Chemistry and Informatics. His research interests include Pilani, India, from 1991 to 1996, where she taught organic and physical QSAR, computer-assisted drug design (CADD), and natural products. chemistry. She received her Ph.D. degree in 1996 under the supervision of Professor S. P. Gupta. Her doctoral work was on QSAR Studies on Anti-HIV Agents. In February 1997, she joined Professor Corwin Hansch as a postdoctoral researcher, and she is currently involved in building a C-QSAR databank. Her research interests include QSAR and computer- assisted drug design. John Katzenellenbogen did his undergraduate and graduate studies in chemistry at Harvard University with E. J. Corey, receiving his Ph.D. degree in 1969 for work on the development of methods for stereospecific olefin synthesis and their application to natural product synthesis. That same year he joined the faculty of the Department of Chemistry at the University of Illinois, where he is now the Swanlund Professor of Chemistry. Dr. Corwin Hansch received his undergraduate education at the University Katzenellenbogen’s research interests have focused on various aspects of Illinois and his Ph.D. in Organic Chemistry from New York University of the structure, function, and use of steroid receptors: He prepared affinity in 1944. After working with the DuPont Company, first on the Manhattan labeling agents for the estrogen receptor and used them to study receptor Project and then in Wilmington, DE, he joined the Pomona College faculty structure, function, and dynamics; he developed an extensive series of in 1946. He has remained at Pomona except for two sabbaticals: one at steroid receptor-based agents labeled with fluorine-18 and technetium- the Federal Institute of Technology in Zurich with Professor Prelog and 99m for imaging receptor-positive tumors of the breast and prostate by the other at the University of Munich with Professor Huisgen. The Pomona radioimaging methods; and he has designed fluorescent probes for steroid group published the first paper on the QSAR approach relating chemical receptors that enable receptor dynamics to be followed in individual cells. structure with biological activity in 1962. Since then, QSAR has received John Katzenellenbogen has trained more than 70 doctoral and postdoctoral widespread attention. In Current Contents (1981/41) he was named as students and published more than 300 articles. He is a fellow of the one of the 300 most cited scientists out of over one million publishing in American Academy of Arts and Sciences. He received the 1995 Aebersold all fields of science for the period 1965−1978. In 1986, Hansch was cited Award of the Society of Nuclear Medicine and a Cope Scholar Award in Current Contents as being one of the 250 most cited primary authors from the American Chemical Society in 1999. for 1984. He is an honorary fellow of the Royal Society of Chemistry and recently received the ACS Award for Computers in Chemical and category are common natural secondary plant Pharmaceutical Research for 1999. metabolitessflavanoids and ligninssthat are present at high levels in common foods, especially those tion, and transcriptional activation on the other.12 derived from soy and whole grains; these compounds The binding of ligands to the hormone-binding do- are considered to be beneficial to human health. main of ER stabilizes the interaction of the receptor The estrogen receptor (ER), the target of these with target sequences in the regulatory region of agents, is a ligand-modulated transcription factor these genes. This binding may be either directly to that regulates the activity of certain genes.12 A specific DNA enhancer sequences or, in some cases, member of the nuclear hormone receptor gene su- to AP1 enhancers through the AP1 transcription perfamily, ER has a multidomain structure, with two factors Fos and Jun. The activation or repression of conserved domains that are responsible for DNA these genes by the ligand receptor complex is then binding on one hand, and ligand binding, dimeriza- mediated by the recruitment by ER of a variety of Comparative QSAR Analysis of Estrogen Receptor Ligands Chemical Reviews, 1999, Vol. 99, No. 3 725 coregulatory proteins that interact with components With this background in the quantitative structure of the basal transcriptional complex
Recommended publications
  • The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
    S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run.
    [Show full text]
  • Steroid Sex Hormones Non Steroid Hormones Fig. A1. Chemical
    Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2015 Steroid sex hormones O OH H H H H H H O Testosterone (T) HO Estrone (E1) OH O H H H H H H O HO 17β-Estradiol (17β-E2) 4-Androstene-3,17-dione (AND) OH OH H OH H H H H H H O HO Nandrolone (NAN) Estriol (E3) OH OH H H H H H H O 17α-Methyltestosterone (17α-MT) HO Ethinylestradiol (EE2) OH O O H HO OH H H H H H H O Prednisolone (PRED) O Progesterone (P) Non steroid hormones HO CH3 HO CH3 H C OH H C OH 3 Diethylstilbestrol (DES) 3 Hexestrol (HEX) Fig. A1. Chemical structure of selected endocrine disruptors. Fig. A2. Scheme of SPE procedure: a) PTFE disks, b) nylon filter membrane. Table A1. Characterization data for mesoporous silicas a Material BET surface Pore volume Pore L0C18 Particle morphology Average particle size 2 -1 3 -1 -1 (m g ) (cm g ) diameter (Å) (mmol C18 g ) (length x wide) SBA-15-C18 796 0.88 76 0.69 Cylindrical 1.4 µm x 750 nm a Amount of octadecyl groups per gram of silica Q3 Q4 Q2 DH 50 0 -50 -100 -150 -200 (ppm) 29 Fig. A3. Si NMR spectrum of SBA-15-C18. 140 0 % Weight Loss T 120 -5 100 s s o L Exothermic Procces 80 t -10 ) h C º g i 60 ( e T W Endothermic Procces -15 % 40 20 -20 0 -25 -20 100 200 300 400 500 600 700 800 T (ºC) Fig.
    [Show full text]
  • Structure and Origin of Uterine and Extragenital L=Ibroids Induced
    Structure and Origin of Uterine and Extragenital l=ibroids Induced Experimentally in the Guinea Pig by Prolonged Administration of Estrogens* Alexander Lipschotz, M.D., and Louis Vargas, Jr., M.D. (From Department o/ Experimental Medicine, National Health Service o/the Republic o/Chile, Santiago, Chile) (Received for publication December 13, x94o) The purpose of this communication is to present the These experimentally induced abdominal tumors findings of a detailed microscopical study of the sites present a smooth surface formed of a capsule com- of origin and stages of development of the subserous posed of flattened superficial cells (Plate 2, Figs. 2-A fibroid tumors induced in guinea pigs by prolonged and 2-B). The cells beneath the capsule resemble administration of estrogens. Details of treatment of fibroblasts. These cells have definite boundaries or the animals are given in the explanations of Plates I- 5. they are separated from each other by collagenous Subserous uterine tumors which can be induced in fibers (Plate 4, Fig. ix-C). guinea pigs by prolonged administration of estrogens, The masses of fibroid tumors arising from the apex as described by Nelson (26, 27), were found to be of the uterine horn may enclose the tubes or large fibroids. Lipschiitz, Iglesias, and Vargas (i3, 18, 22) tubal cysts. The demarcation between the muscular have shown that extragenital tumors in the abdominal coat of the tube and the tumor is not always sharp. cavity, induced by estrogens, also were fibroids. The In some instances, especially when the apical fibroid localization of these tumo~:s at various sites on the is small, the tumor is in close contact with an abun- uterus, pancreas, kidney, spleen, etc., have been de- dance of smooth muscle and adipose tissue (Plate 2, scribed by Iglesias (5), Vargas and Lipschiitz (32), Fig.
    [Show full text]
  • Estrogen-Induced Endogenous DNA Adduction
    Proc. Natl. Acad. Sci. USA Vol. 83, pp. 5301-5305, July 1986 Medical Sciences Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer (estradiol/synthetic estrogens/renal carcinoma/Syrian hamster/32P-labeling analysis) J. G. LIEHR*, T. A. AVITTSt, E. RANDERATHt, AND K. RANDERATHtt *Department of Pharmacology, University of Texas Medical Branch, Galveston, TX 77550; and tDepartment of Pharmacology, Baylor College of Medicine, Houston, TX 77030 Communicated by Paul C. Zamecnik, March 24, 1986 ABSTRACT In animals and humans, estrogens are able to but the mechanism of this effect has not been elucidated. In induce cancer in susceptible target organs, but the mecha- view ofthe extensive use ofcompounds with estrogenic activity nism(s) of estrogen-induced carcinogenesis has not been eluci- in human medicine (20, 21) and in agriculture (22) and the dated. A well-known animal model is the development of renal occurrence of estrogenic compounds as contaminants in food carcinoma in estrogen-treated Syrian hamsters. Previous work (22, 23), it is important to define how these compounds cause demonstrated the presence of covalent DNA addition products cancer. (adducts) in premalignant kidneys of hamsters exposed to the A central question to be addressed in this context is whether synthetic estrogen, diethylstilbestrol, a known human carcin- or not estrogens, like the majority of chemical carcinogens, ogen. In the present study, the natural hormone, 178-estradiol, induce covalent DNA alterations in the target tissue of and several synthetic steroid and stilbene estrogens were exam- carcinogenesis in vivo. In the present study, experiments were ined by a 32P-postlabeling assay for their capacity to cause carried out to search for adduct formation in an established covalent DNA alterations in hamster kidney.
    [Show full text]
  • Hormone Replacement Therapy and Osteoporosis
    This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting.
    [Show full text]
  • Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol Plus Hexestrol*T
    Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol plus Hexestrol*t A. ANGRIST, P. CAPURRO, AND B. MOUMGIS (Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York 61, N.Y.) SUMMARY The effects of estrogens were studied with and without foreign body (rough glass beads and paraffin pellets) on the metaplasia of the bladder of rats on stock main tenance diet and on a vitamin A-deficient diet. Estradiol increased the degree of metaplasia in the bladder of rats when combined with vitamin A deficiency and/or foreign body stimulation. Estradiol affected bladder epithelium already made squamous more effectively than it did the normal transitional uroepithelium. A high dose of hexestrol, when added to estradiol, showed no enhance ment of the degree of metaplasi.a by estradiol benzoate in the bladder of the rat. The combination of vitamin A deficiency, foreign body in situ, and estrogenadminis tration was an effective means of obtaining keratinizing squamous metaplasia in the urinary bladder for studies of its developmental and reversal changes. In a previous presentation (4) the relation of The animals were divided into the following different forms of foreign-body irritation and of groups (the number of rats surviving with tissue vitamin A deficiency to squamous metaplasia in for study and the total number in each group mi the bladders of rats was reported. It is also known tinily are given following each group): that estrogens will cause squamous metaplasia. I. Stock diet + estradiol (6 survivals/lI rats) The metaplasia following estrogen administration II.
    [Show full text]
  • Use of Estrogen-Dihydropyridine Compounds For
    Europaisches Patentamt J European Patent Office © Publication number: 0 220 844 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 86307536.2 © int. ci.<: A61K 31/57 A61 K , 31/565 , A61K 31/44 © Date of filing: 01.10.86 The title of the invention has been amended © Applicant: UNIVERSITY OF FLORIDA (Guidelines for Examination in the EPO, A-lll, 207 Tigert Hall 7.3). Gainesville Florida 32611 (US) @ Inventor: Bodor, Nicholas S. ® Priority: 22.10.85 US 790159 7211 Southwest 97th Lane Gainesville Florida 32608(US) © Date of publication of application: Inventor: Estes, Kerry S. 06.05.87 Bulletin 87/19 5604 Southwest 83rd Drive Gainesville Florida 32608(US) © Designated Contracting States: Inventor: Simpkins, James W. AT BE CH DE ES FR GB GR IT LI LU NL SE 1722 Northwest 11th Road Gainesville Florida 32605(US) © Representative: Pendlebury, Anthony et al Page, White & Fairer 5 Plough Place New Fetter Lane London EC4A 1HY(GB) © Use of estrogen-dihydropyridlne compounds for weight control. © The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridines*pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an I estradiol derivative, namely, 1 7/3-[(1 -methyl-1 ,4-dihydro-3-pyridinyl)carbonyloxy]estra-1 ,3,5(1 0)-trien-3-ol.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Reversal of Acquired Resistance to Doxorubicin in P388 Murine Leukemia Cells by Tamoxifen and Other Triparanol Analogues1
    [CANCER RESEARCH 44, 4392-4395, October 1984] Reversal of Acquired Resistance to Doxorubicin in P388 Murine Leukemia Cells by Tamoxifen and Other Triparanol Analogues1 A. Ramu,2 D. Glaubiger, and Z. Fuks Department of Radiation and Clinical Oncology, Hadassah University Hospital, P. 0. Box 12000, Jerusalem, Israel 91120 [A. R., Z. F], and The Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20205 [D. G.] ABSTRACT We now report on the reduction of doxorubicin resistance by a different group of tricyclic compounds, tamoxifen and other The effects of the triparanol analogues chlorotrianisene, clom- triparanol analogues, and bring evidence that this effect is not a iphene, tamoxifen, 5-[p-(fluoren-9-ylidenemethyl)phenyl]-2-piper- result of the antiestrogenic activity of these compounds. idineethanol (MDL 10393), MDL 8917v, nafoxidine, 2-[p-(6-meth- oxy-2-phenylinden-3-yl)phenoxy]triethylamine (U-11555A), 2-[p- (3,4-dihydro- 6- methoxy-2 - phenyl -1 - naphthyl)phenoxy]triethyl- MATERIALS AND METHODS amine (U-10520A), and nitromifene, as well as triparanol itself, Cell Culture and Determination of Drug Sensitivity. These were were studied in the P388 murine leukemia cell line and in a carried out as described previously (9). Briefly, P388 murine leukemia doxorubicin-resistant subline (P388/ADR). At noninhibitory con cells and a doxorubicin-resistant subline (P388/ADR)3 were maintained centrations, all the analogues increased the sensitivity of P388/ in RPMI 1640 (Grand Island Biological Co., Grand Island, NY) supple ADR cells to doxorubicin but did not have such an effect on the mented with 10% fetal calf serum (Grand Island Biological Co.), 10 /¿M doxorubicin-sensitive cells.
    [Show full text]
  • Supplemental Figure
    ● Agonist ● Antagonist ● Interference AR AUC 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 17beta−Trenbolone 5alpha−Dihydrotestosterone 17−Methyltestosterone Testosterone propionate Norethindrone Norgestrel GSK232420A 4−Androstene−3,17−dione Progesterone 17beta−Estradiol Mifepristone 17alpha−Ethinylestradiol Hydroxyflutamide 17alpha−Hydroxyprogesterone Corticosterone Nilutamide Basic Blue 7 Triphenyltin hydroxide Bicalutamide Tributyltin benzoate 17alpha−Estradiol Gentian Violet Equilin Zinc pyrithione Triticonazole Fenitrothion Mestranol Tributyltin methacrylate 2,2−Bis(4−hydroxyphenyl)−1,1,1 Dibutyltin dichloride Flutamide Methyltrioctylammonium chlorid Rhodamine 6G Tributyltetradecylphosphonium Emamectin benzoate Phenylmercuric acetate Cyproterone acetate Chlorothalonil 9−Phenanthrol 2,2',4,4'−Tetrahydroxybenzophe Melengestrol acetate Dehydroepiandrosterone 1−Chloro−2,4−dinitrobenzene SSR240612 Methylbenzethonium chloride Vinclozolin Tetraconazole Ziram Didecyldimethylammonium chlori Econazole nitrate Myristyltrimethylammonium chlo Clorophene Abamectin Octyl gallate 2−Chloro−4−phenylphenol Bisphenol A Propanil Dexamethasone sodium phosphate meso−Hexestrol Dichlorophen Hydroxyprogesterone caproate SSR241586 Bisphenol AF Prednisone Dichlone Reserpine Chlorobenzilate Diethylstilbestrol 3−Hydroxyfluorene Procymidone 4−Cumylphenol 4−Hydroxytamoxifen Napropamide PharmaGSID_48519 Clomiphene citrate (1:1) Chlorhexidine diacetate Tebuconazole Imazalil Dinocap PharmaGSID_48513 Linuron Prochloraz Zoxamide TDCPP Captan 3,3'−Dimethoxybenzidine dihydr 4−Phenylphenol
    [Show full text]
  • Fluoroestradiol
    Investigator’s Brochure for [18F]Fluoroestradiol AN INVESTIGATIONAL POSITRON EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICAL FOR INJECTION, INTENDED FOR USE AS AN IN VIVO DIAGNOSTIC FOR IMAGING ESTROGEN RECEPTORS IN TUMORS IND # put your IND# here Put your Name and Address here IB Edition Number: 6 IB Edition Date/Release Date: November 10, 2020 Investigator’s Brochure: [18F]FES Table of Contents 1. SUMMARY ...................................................................................................................................... 3 2. INTRODUCTION ............................................................................................................................... 4 3. PHYSICAL, CHEMICAL, AND PHARMACEUTICAL PROPERTIES AND FORMULATION .......................... 4 3.1. AGENT DESCRIPTION ............................................................................................................................ 4 3.2. CHEMICAL STRUCTURE ........................................................................................................................ 5 3.3. FINAL PRODUCT SPECIFICATIONS ......................................................................................................... 5 4. NONCLINICAL STUDIES .................................................................................................................... 7 4.1. NONCLINICAL PHARMACOLOGY OF FES AND ESTRADIOL .................................................................... 7 4.2. PHARMACOKINETICS AND METABOLISM OF FES IN ANIMALS .............................................................
    [Show full text]
  • Hexestrol | Medchemexpress
    Inhibitors Product Data Sheet Hexestrol • Agonists Cat. No.: HY-B1662 CAS No.: 84-16-2 Molecular Formula: C₁₈H₂₂O₂ • Molecular Weight: 270.37 Screening Libraries Target: Estrogen Receptor/ERR Pathway: Others Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (369.86 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.6986 mL 18.4932 mL 36.9864 mL Stock Solutions 5 mM 0.7397 mL 3.6986 mL 7.3973 mL 10 mM 0.3699 mL 1.8493 mL 3.6986 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (7.69 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.69 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.69 mM); Clear solution BIOLOGICAL ACTIVITY Description Hexestrol is a nonsteroidal synthetic estrogen, with a Ki of 0.06 and 0.06 nM for estrogen receptor alpha (ERα) and ERβ. Hexestrol can be used for the research of the diseases caused by estrogen deficiencym, and it also can increase the weight of cattle[1][2][3]. IC₅₀ & Target ERα ERβ 0.06 nM (Ki) 0.06 nM (Ki) In Vivo Hexestrol (3 and 6 mg/kg; i.p.
    [Show full text]